Drug Trial Radar · NCT04046445
Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Jan 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
96
Planned (sponsor's estimate)
Start
Jul 22, 2019
Primary completion
May 31, 2025
Study completion Aug 31, 2025
Sponsor
- Lead sponsor
- Amal TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- Boehringer Ingelheim
- First posted
- Aug 6, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, non-randomised Phase 1b study to evaluate the safety and tolerability of ATP128 alone or in combination with BI 754091 and of heterologous prime-boost ATP128 + VSV-GP128 in combination with BI 754091. ATP128 is a self-adjuvanted chimeric recombinant protein vaccine being developed in combination with programmed cell death 1 (PD-1) blockade for the treatment of microsatellite stable (MSS) patients not responding to PD-1 blockade. The PD-1 inhibitor being tested with ATP128 is the BI 754091 (Ezabenlimab) compound which belongs to the human immunoglobulin G4 (IgG4) subclass of antibodies. VSV-GP is a recombinant chimeric vesicular stomatitis virus (VSV, Indiana strain Rhabdoviridae) which carries the envelope glycoprotein (GP) of the visceral non neurotropic WE-HPI strain of the Lymphocytic choriomeningitis virus (LCMV, Arenaviridae) instead of the native VSV glycoprotein (G) and is developed as integral part of the prime-boost regimen together with ATP128. The Sponsor plans to enrol 96 patients with histologically or cytologically confirmed stage IV colorectal cancer coming form three different patient populations: * Cohort 1a: 6 patients with stage IV colorectal cancer (CRC) having failed standard of care (SoC) therapies * Cohorts 1b, 2a, 2c: 30 patients with stage IV microsatellite stable/mismatch repair-proficient (MSS/MMRp) CRC being in stable disease (SD) or partial response (PR) after first line of SoC (4-6 months duration at minimum) * Cohorts 2b, 4b: 30 patients with stage IV MSS/MMRp liver-limited disease Patients eligible for this study will be enrolled in one of the 8 cohorts depending on their disease: * Patients in Cohort 1a will receive ATP128 as single agent * Patients in Cohorts 1b, 2a, 2b, 2c will receive ATP128 in combination with BI 754091 * Patients in Cohorts 3, 4a, 4b will receive ATP128 and VSV-GP128 in combination with BI 754091
Conditions
- Colorectal Cancer
- MSS
- Stage IV Colon Cancer
- Stage IV Rectal Cancer
- Metastatic Colorectal Cancer
- Liver Metastasis Colon Cancer
Interventions
ATP128Drug
5-6 SC injections
BI 754091Drug
≥ 7 IV infusions
VSV-GP128Drug
1 single IV injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate safety and tolerability by measure of incidence of treatment-emergent adverse events (AEs) and serious adverse events (SAEs) graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0Time frame: 1 year
- valuate anti-tumor effect of study treatment by measure of Progression-free survival (PFS)Time frame: 6 months
Locations
12 sites in 4 countries. Site status is shown where the registry gives one.
Honor Health Institute
Scottsdale, Arizona
University of Southern California
Los Angeles, California
University of Colorado Anschutz Medical Campus
Aurora, Colorado
NYU Langone Health
New York, New York
Weill Cornell Medicine
New York, New York
Duke Cancer Institute
Durham, North Carolina
University of Texas, MD Anderson Cancer Center
Houston, Texas
University Hospital Antwerpen
Edegem, Belgium
University Hospital Leuven
Leuven, Belgium
University Medicine Mainz
Mainz, Germany
Geneva University Hospitals
Geneva, Switzerland
University Hospital Zurich
Zurich, Canton of Zurich, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.